Further findings for interferon-beta-1a in RRMS

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1657, 2008-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alemtuzumab shows further benefits over INF-β-1b for RRMS

By  

Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a: Modelling the Clinical and Economic Implications

By Guo Shien   Bozkaya Duygu  

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 39-53

Adis International

Access to resources Recommend Favorite

Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 1, 2009-03 ,pp. : 14-28

Bentham Science Publishers

Access to resources Recommend Favorite

Interferon (IFN)- -1a shows comparable efficacy to IFN- -1b in patients with RRMS

By  

Inpharma, Vol. 1, Iss. 1318, 2001-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Interferon-beta Inhibits Th17 Cell Differentiation in Patients with Multiple Sclerosis

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 10, Iss. 2, 2010-06 ,pp. : 161-167

Bentham Science Publishers

Access to resources Recommend Favorite